clinmedКлиническая медицинаClinical Medicine (Russian Journal)0023-21492412-1339ООО «Медицинское информационное агентство»10.30629/0023-2149-2024-102-3-252-256clinmed-786Research ArticleВ ПОМОЩЬ ПРАКТИЧЕСКОМУ ВРАЧУGUIDELINES FOR PRACTITIONERSCOVID-19 и сахарный диабет: риски для здоровьяCOVID-19 and diabetes: health riskshttps://orcid.org/0000-0001-7986-8010СоколоваЕ. С.SokolovaE. S.

Соколова Елизавета Сергеевна — cпециалист, ординатор

Пермь

Elizaveta S. Sokolova — Specialist, Resident

Perm

https://orcid.org/0000-0002-6856-0616ПаламаренкоМ. А.PalamarenkoM. A.

Паламаренко Мария Александровна

Пермь

Mariya A. Palamarenko

Perm

https://orcid.org/0000-0001-5600-6661ОсиповА. А.OsipovA. A.

Осипов Андрей Александрович — cпециалист, ординатор

Ставрополь

Andrey A. Osipov — Specialist, Resident

Stavropol

https://orcid.org/0000-0002-2712-0227ЧаулинА. М.ChaulinA. M.

Чаулин Алексей Михайлович — канд. мед. наук, научный сотрудник

443099, Самара

Aleksey M. Chaulin — Dr of Sci. (Med.), Research Associate

Samara

https://orcid.org/0000-0003-4246-9512ЕлисееваЕ. В.EliseevaE. V.

Елисеева Евгения Владимировна — специалист, ординатор 

Пермь

Evgeniya V. Eliseeva — Specialist, Resident

Perm

evgesha_eliseeva@rambler.ruhttps://orcid.org/0000-0001-5723-0948КорякинЕ. С.KoryakinE. S.

Корякин Егор Сергеевич — специалист, ординатор

Пермь

Egor S. Koryakin — Specialist, Resident

Perm

ФГБУ ВО «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Минздрава РоссииРоссияAcademician E.A. Wagner Perm State Medical University of the Ministry of Healthcare of RussiaRussian FederationФГБУ ВО «Ставропольский государственный медицинский университет» Минздрава РоссииРоссияStavropol State Medical University of the Ministry of Healthcare of RussiRussian FederationНИИ кардиологии ФГБОУ ВО Самарский государственный медицинский университет Министерства здравоохранения Российской ФедерацииРоссияSamara Regional Clinical Cardiology DispensaryRussian Federation2024020620241023252256Copyright © Соколова Е.С., Паламаренко М.А., Осипов А.А., Чаулин А.М., Елисеева Е.В., Корякин Е.С., 20242024Соколова Е.С., Паламаренко М.А., Осипов А.А., Чаулин А.М., Елисеева Е.В., Корякин Е.С.Sokolova E.S., Palamarenko M.A., Osipov A.A., Chaulin A.M., Eliseeva E.V., Koryakin E.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinmedjournal.com/jour/article/view/786

В эпоху пандемии COVID-19 множество привычных процессов пришлось адаптировать из-за разных ограничений и высокой нагрузки на медицинских работников. В частности, для снижения риска заражения коронавирусом стали чаще использовать технологии дистанционного обслуживания пациентов. Данное исследование направлено на анализ влияния пандемии COVID-19 и связанных с ней ограничений на доступ к бесплатным образовательным курсам по диабету, динамику заболевания и осведомленность пациентов о необходимых методах лечения. Изучались изменения степени удовлетворенности пациентов онлайн-обучением по сравнению с традиционным очным форматом, а также изменения в приеме необходимых медикаментов при регулярном обучении и консультациях. Авторы исследования описали возможные причины изменений в эффективности обучения и предложили меры для оптимизации процессов лечения и информирования пациентов на территории России. Исследование показало, что пандемия COVID-19 способствовала снижению участия пациентов в образовательных программах по диабету. Это могло произойти из-за страха перед заражением, незнания о наличии таких программ и социально-экономического неравенства.

During the COVID-19 pandemic, many familiar processes had to be adapted due to various restrictions and high workload on healthcare workers. In particular, to reduce the risk of coronavirus infection, remote patient care technologies have been used more frequently. This study aims to analyze the impact of the COVID-19 pandemic and related restrictions on access to free educational courses on diabetes, disease dynamics, and patient awareness of necessary treatment methods. Changes in patient satisfaction with online learning compared to traditional face-to-face formats were studied, as well as changes in medication adherence with regular education and consultations. The authors described possible reasons for changes in the effectiveness of education and proposed measures to optimize treatment processes and patient information in Russia. The study showed that the COVID-19 pandemic led to a decrease in patient participation in educational programs on diabetes. This could have been due to fear of infection, lack of awareness of such programs, and socio-economic inequality.

пандемия коронавируса COVID-19диабетпоказатель гемоглобинарецепторыингибиторыCOVID-19 coronavirus pandemicdiabeteshemoglobin levelsreceptorsinhibitorsReferencesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) What is diabetes? Diabetes Overview. 2016.National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) What is diabetes? Diabetes Overview. 2016.Howard-Thompson A. et al. Type 2 diabetes mellitus: outpatient insulin management. American Family Physician. 2018;97(1):29– 37. DOI: 10.13655/1.6.1234567Howard-Thompson A. et al. Type 2 diabetes mellitus: outpatient insulin management. American Family Physician. 2018;97(1):29– 37. DOI: 10.13655/1.6.1234567Roglic G. Diabetes. World Health Organization (WHO). 2022.Roglic G. Diabetes. World Health Organization (WHO). 2022.Дедов И.И., Концевая А.В., Шестакова М.В., Белоусов Ю.Б., Баланова Ю.А., Худяков М.Б., Карпов О.И. Экономические затраты на сахарный диабет 2 типа и его основные сердечно-сосудистые осложнения в Российской Федерации. Сахарный диабет. 2016;19(6):518–526. DOI: 10.13655/1.6.1234567Dedov I.I., Kontsevaya A.V., Shestakova M.V., Belousov Yu.B., Balanova Yu.A., Khudyakov M.B., Karpov O.I. Economic burden of type 2 diabetes and its major cardiovascular complications in the Russian Federation. Sakharnyy diabet. 2016;19(6):518–526. (In Russian). DOI: 10.13655/1.6.1234567Попович Л.Д., Шестакова М.В., Потапчик Е.Г., Майоров А.Ю., Викулова О.К. Выгодно ли государству обеспечивать больных сахарным диабетом, находящихся на инсулинотерапии, средствами для проведения самоконтроля уровня глюкозы крови по нормативным потребностям? Сахарный диабет. 2017;20(2):108– 118. DOI: 10.13655/1.6.1234567Popovich L.D., Shestakova M.V., Potapchik E.G., Mayorov A.Yu., Vikulova O.K. Is it beneficial for the state to provide diabetic patients on insulin therapy with self-monitoring blood glucose devices according to regulatory needs? Sakharnyy diabet. 2017;20(2):108–118. (In Russian). DOI: 10.13655/1.6.1234567An J. et al. Prevalence and incidence of microvascular and macro vascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Research and Care. 2021;9(1):1–10. DOI: 10.13655/1.6.1234567An J. et al. Prevalence and incidence of microvascular and macro vascular complications over 15 years among patients with incident type 2 diabetes. BMJ Open Diabetes Research and Care. 2021;9(1):1–10. DOI: 10.13655/1.6.1234567Глущенко В.А., Ирклиенко Е.К. Сердечно-сосудистая заболеваемость — одна из важнейших проблем здравоохранения. Медицина и организация здравоохранения. 2019;4(1):56–63. DOI: 10.13655/1.6.1234567Glushchenko V .A ., Irklyenko E .K. Cardiovascular disease — one of the most important healthcare problems. Meditsina i organizatsiya zdra vo okhraneniya. 2019;4(1):56–63. (In Russian). DOI: 10.13655/1.6.1234567Cardoso R. et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. Clinical Medicine. 2021;36:100933. DOI: 10.13655/1.6.1234567Cardoso R. et al. SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. Clinical Medicine. 2021;36:100933. DOI: 10.13655/1.6.1234567Gerstein H.C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. New England Journal of Medicine. 2021;385(10):896–907. DOI: 10.13655/1.6.1234567Gerstein H.C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. New England Journal of Medicine. 2021;385(10):896–907. DOI: 10.13655/1.6.1234567American Heart Association (AHA) Living healthy with diabetes. 2021.American Heart Association (AHA) Living healthy with diabetes. 2021.Diabetes Prevention Program Research Group et al. Long-term eff ects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology. 2015;3(11):866–875. DOI: 10.13655/1.6.1234567Diabetes Prevention Program Research Group et al. Long-term eff ects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. The Lancet Diabetes & Endocrinology. 2015;3(11):866–875. DOI: 10.13655/1.6.1234567Association of Diabetes Care and Education Specialists (ADCES). How diabetes education helps patients. 2021.Association of Diabetes Care and Education Specialists (ADCES). How diabetes education helps patients. 2021.Rochmah N. et al. Quality of life differences in pre- and posteducational treatment in type 1 diabetes mellitus during COVID-19. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:2905–2911. DOI: 10.13655/1.6.1234567Rochmah N. et al. Quality of life differences in pre- and posteducational treatment in type 1 diabetes mellitus during COVID-19. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:2905–2911. DOI: 10.13655/1.6.1234567Ascension Stories. A faith-based healthcare organization. [Electronic resource]. URL: https://healthcare.ascension.org/ (Access date 30.12.2022)Ascension Stories. A faith-based healthcare organization. [Electronic resource]. URL: https://healthcare.ascension.org/ (Access date 30.12.2022)Gurdeep S. et al. Diabetes education and the COVID-19 pandemic. J. Endocrinol 2022;6(1):000172.Gurdeep S. et al. Diabetes education and the COVID-19 pandemic. J. Endocrinol 2022;6(1):000172.Hill-Briggs F. et al. Social determinants of health and diabetes: a scientifi c review. Diabetes care. 2021;44(1):258–279. DOI: 10.13655/1.6.1234567Hill-Briggs F. et al. Social determinants of health and diabetes: a scientifi c review. Diabetes care. 2021;44(1):258–279. DOI: 10.13655/1.6.1234567Siminerio L.M. et al. The National Diabetes Education Program at 20 years: lessons learned and plans for the future. Diabetes care. 2018;41(2):209–218. DOI: 10.13655/1.6.1234567Siminerio L.M. et al. The National Diabetes Education Program at 20 years: lessons learned and plans for the future. Diabetes care. 2018;41(2):209–218. DOI: 10.13655/1.6.1234567Quinn L.M. et al. Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. Diabetic Medicine. 2021;38(3). DOI: 10.13655/1.6.1234567Quinn L.M. et al. Use of MyDesmond digital education programme to support self-management in people with type 2 diabetes during the COVID-19 pandemic. Diabetic Medicine. 2021;38(3). DOI: 10.13655/1.6.1234567Hartmann-Boyce J. et al. Diabetes and COVID-19: risks, mana gement, and learnings from other national disasters. Diabetes care. 2020;43(8):1695–1703. DOI: 10.13655/1.6.1234567Hartmann-Boyce J. et al. Diabetes and COVID-19: risks, mana gement, and learnings from other national disasters. Diabetes care. 2020;43(8):1695–1703. DOI: 10.13655/1.6.1234567Zhang Z., Monro J., Venn B.J. Development and evaluation of an internet-based diabetes nutrition education resource. Nutrients. 2019;11(6):1217. DOI: 10.13655/1.6.1234567Zhang Z., Monro J., Venn B.J. Development and evaluation of an internet-based diabetes nutrition education resource. Nutrients. 2019;11(6):1217. DOI: 10.13655/1.6.1234567

The authors declare that there are no conflicts of interest present.